Asciminib

Active ingredient description

Asciminib is a potent inhibitor of ABL/BCR::ABL1 tyrosine kinase. Asciminib inhibits the ABL1 kinase activity of the BCR::ABL1 fusion protein by specifically targeting the ABL myristoyl pocket.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
Classification
L01EA06
L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EA BCR-ABL tyrosine kinase inhibitors
Discover more medicines within L01EA06

Product monographs

Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):

Title
Type
Country
SCEMBLIX Film-coated tablet
Summary of Product Characteristics (SPC)

Medicines

Asciminib is the active ingredient of these drugs:

Drug
Countries
SCEMBLIX

Australia Canada France Lithuania Romania

Structural formula

Graphic representation of the active ingredient's molecular structure

Chemical formula: C₂₀H₁₈ClF₂N₅O₃
Molecular mass: 449.84 g/mol

External identifiers

CAS Substance: 1492952-76-7
DrugBank Drug: DB12597
KEGG Drug: D11403
PubChem Compound: 72165228
RxNorm Ingredient: 2584304
UNII Identifier: L1F3R18W77
ASCIMINIB
 
Next: Usage >